Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.

Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, Bringhen S, Musto P, Pregno P, Caravita T, Ciccone G, Boccadoro M.

Hematol J. 2004;5(4):318-24.

PMID:
15297848
2.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
3.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

4.

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.

Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.

Eur J Haematol. 2005 Nov;75(5):391-5.

PMID:
16191088
5.

Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: a clinical study of 110 patients in China.

Li Y, Hou J, Wang D, Fu W, Yuan Z, Chen Y, Tao Z.

Leuk Lymphoma. 2006 Dec;47(12):2593-600.

PMID:
17169804
6.

Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.

Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.

Cancer. 2007 Aug 15;110(4):824-9.

7.

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H.

Clin Cancer Res. 2002 Nov;8(11):3377-82.

8.

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.

Zamagni E, Petrucci A, Tosi P, Tacchetti P, Perrone G, Brioli A, Pantani L, Zannetti B, Terragna C, Baccarani M, Cavo M.

Ann Hematol. 2012 Mar;91(3):419-26. doi: 10.1007/s00277-011-1320-2. Epub 2011 Sep 8.

PMID:
21901342
9.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
10.

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M.

Haematologica. 2001 Apr;86(4):399-403.

11.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

12.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
13.

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.

14.

[The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].

Qi PJ, Wang YF, Xu Y, Li YN, Zou DH, Zhao YZ, Xiao ZJ, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):226-9. Chinese.

PMID:
18843974
15.

[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].

Yuan ZG, Hou J, Wang DX, Fu WJ, Chen YB, Xi H.

Ai Zheng. 2007 Dec;26(12):1369-72. Chinese.

PMID:
18076804
16.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA.

Eur J Haematol. 2009 Jun;82(6):426-32. doi: 10.1111/j.1600-0609.2009.01257.x. Epub 2009 Mar 19.

17.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study.

Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10.

18.

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.

Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N, Manko J, Jedrzejczak WW, Charlinski G, Usnarska-Zubkiewicz L, Skotnicki A, Wolska-Smolen T, Piszcz J, Kloczko J.

Leuk Res. 2010 Oct;34(10):1330-5. doi: 10.1016/j.leukres.2010.05.003. Epub 2010 Jun 2.

PMID:
20627385
19.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.

Blood. 2002 Nov 1;100(9):3063-7.

20.

[Clinical study of multiple myeloma: a report of 182 cases].

Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ.

Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):972-7. Chinese.

PMID:
20646647
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk